Navigation Links
Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
Date:4/7/2009

DENVER, April 7 /PRNewswire/ -- Pharmatech Oncology, Inc., a Research Management Organization (RMO), has been selected as one of the presenting companies at the Company Showcase during BIOZONA 2009 - Arizona's Annual Bioscience Industry Conference at the Sheraton Phoenix Downtown on April 7th in Phoenix, Arizona.

Matthew B. Wiener, PharmD, COO and Founder of Pharmatech Oncology, will present during the first session of the conference. The presentation will cover topics including: the science, business and markets on which the company is based, recent accomplishments, and strategic partnerships.

Dr. Wiener will focus on the many accomplishments for Pharmatech Oncology in cancer clinical trials utilizing the Just-In-Time (JIT) enrollment methodology. The aim of the Just-In-Time program is to shorten the time to enroll cancer patients into clinical trials and also expand the number of patients being offered trials. "Pharmatech Oncology is honored to be selected from a large number of applicants to be one of eighteen companies presenting at this distinguished BIOZONA event. We anticipate great exposure for our Just-In-Time clinical trial program, as we feel it is revolutionizing the enrollment process of adult cancer patients into clinical trials," states Dr. Wiener. For further information about BIOZONA 2009, please visit the event web site at http://www.azbio.org/Biozona2009.asp.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. With Data Management as a separate business entity, it allows for management of data for other types
'/>"/>

SOURCE Pharmatech Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
2. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
3. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
4. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
5. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
6. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
7. Pharmatech 2.0: Introducing Pharmatech Oncology
8. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
9. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
10. WuXi PharmaTech Announces Third Quarter 2008 Results
11. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, Inc. ... treatments for urological and related conditions, announced today that ... private placement convertible note financing, raising a total of ... totaling $3.175 million. Josh Disbrow ... this private placement are intended to be used to ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
(Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... international team of researchers has designed a new graphite-based, ... help material scientists create the next generation of electronic ... Virginia Commonwealth University; Peking University in Beijing, China; the ... University in Sedai, Japan; used theoretical computer modeling to ...
... , , , RICHMOND, Calif., ... today announced that it will present at the BioCentury Thomson Reuters ... at 11:00 am EDT. , , A live ... the investor webpage at www.transcept.com . , ...
... , , , HAYWARD, ... today that it has completed the second closing of its ... capital raised in this round to $5.4 million. , ... the development of its proprietary diagnostic tests based on the ...
Cached Biology Technology:Researchers design new graphene-based, nano-material with magnetic properties 2Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009 2Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009 3Transcept Pharmaceuticals to Present at the BioCentury Thomson Reuters Newsmakers in the Biotech Industry Conference on September 16, 2009 4ACD Completes the Second Closing of Series A Financing and Initiates Services for Biomarker Validation and Companion Diagnostic Development 2
(Date:8/6/2015)... JOSE, Calif. , Aug. 6, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... TouchPad technologies on Windows 10. Microsoft leveraged Synaptics, ... to the operating system. Through ... drivers are fully certified with Microsoft,s Precision TouchPad ...
(Date:8/5/2015)... VIEW, Calif. , Aug. 5, 2015 ... exhibits continuous growth in applications, penetration into newer sectors, ... after year. The global biosensors space has seen the ... exited the market so far. (Photo - ... Frost & Sullivan, Analysis of the Global Biosensors ...
(Date:8/3/2015)... Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... today announced that members of the executive management team ... Crest Global Technology Leadership Forum on Tuesday, August 11, ... be held at the Sonnenalp Resort in ... may include forward-looking information. An audio webcast of the ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
... in the distant future, miniature, medically-savvy computers will roam ... the spot by releasing a suitable drug, without any ... must be sufficiently small to fit into body cells. ... cellular systems. These challenges can be best addressed by ...
... pathogen attacks a plant, infection usually follows after the plant,s ... the University of California, Riverside focused on Phytophthora , ... th century by infecting potato plants, and deciphered how ... genus Phytophthora contains many notorious pathogens of crops. ...
... fibers go, there,s never been anything quite like spider silk. Stretch ... up. It is five times stronger than steel and can expand ... back like new. Ounce-for-ounce spider silk is even stronger than Kevlar, ... understandable to think that science knows all there is to know ...
Cached Biology News:A genetic device performs DNA diagnosis 2Scientists identify genetic mechanism that contributed to Irish Famine 2Scientists identify genetic mechanism that contributed to Irish Famine 3Stanford researcher sheds new light on the mysteries of spider silk 2Stanford researcher sheds new light on the mysteries of spider silk 3Stanford researcher sheds new light on the mysteries of spider silk 4
... Blot includes 7 ... isolated from Alzheimer's-diseased brain ... postcentral gyrus, frontal lobe, ... occipital lobe and cerebellum. ...
... use spatulas have been designed to save ... for those interested in eliminating the recycling ... spatula is individually packaged, RNase/DNase free, non-pyrogenic ... a new product number, created to easily ...
... harvesting of cells • Blade design minimizes ... the growth surface • Designed for use ... wrapped • Sterilized by gamma radiation and ... a new product number, created to easily ...
... Corning single use spatulas have been designed ... They are for those interested in eliminating ... spatulas. Each spatula is individually packaged, RNase/DNase ... number is a new product number, created ...
Biology Products: